DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC
TAK-390MR_204
Phase 2 small_molecule active
Quick answer
DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC for Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active